DE69427364T2 - METHOD AND COMPOSITIONS FOR TREATING BCR-ABL ASSOCIATED LEUKEMIA AND OTHER CELL-POLLIFERATIVE DISORDERS - Google Patents

METHOD AND COMPOSITIONS FOR TREATING BCR-ABL ASSOCIATED LEUKEMIA AND OTHER CELL-POLLIFERATIVE DISORDERS

Info

Publication number
DE69427364T2
DE69427364T2 DE69427364T DE69427364T DE69427364T2 DE 69427364 T2 DE69427364 T2 DE 69427364T2 DE 69427364 T DE69427364 T DE 69427364T DE 69427364 T DE69427364 T DE 69427364T DE 69427364 T2 DE69427364 T2 DE 69427364T2
Authority
DE
Germany
Prior art keywords
compositions
complexes
bcr
disorders
polliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427364T
Other languages
German (de)
Other versions
DE69427364D1 (en
Inventor
Joseph Schlessinger
L Gishizky
M Pendergast
Harald App
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
New York University NYU
Duke University
Original Assignee
University of Durham
New York University Medical Center
Sugen LLC
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Durham, New York University Medical Center, Sugen LLC, Duke University filed Critical University of Durham
Publication of DE69427364D1 publication Critical patent/DE69427364D1/en
Application granted granted Critical
Publication of DE69427364T2 publication Critical patent/DE69427364T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
DE69427364T 1993-09-28 1994-09-28 METHOD AND COMPOSITIONS FOR TREATING BCR-ABL ASSOCIATED LEUKEMIA AND OTHER CELL-POLLIFERATIVE DISORDERS Expired - Fee Related DE69427364T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12792293A 1993-09-28 1993-09-28
US08/246,441 US6066463A (en) 1993-09-28 1994-05-20 Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
PCT/US1994/011067 WO1995009365A1 (en) 1993-09-28 1994-09-28 Methods and compositions for treatment of bcr-abl associated leukemias and other cell proliferative disorders

Publications (2)

Publication Number Publication Date
DE69427364D1 DE69427364D1 (en) 2001-07-05
DE69427364T2 true DE69427364T2 (en) 2002-06-20

Family

ID=26826088

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427364T Expired - Fee Related DE69427364T2 (en) 1993-09-28 1994-09-28 METHOD AND COMPOSITIONS FOR TREATING BCR-ABL ASSOCIATED LEUKEMIA AND OTHER CELL-POLLIFERATIVE DISORDERS

Country Status (10)

Country Link
US (3) US6066463A (en)
EP (1) EP0721586B1 (en)
JP (1) JP3606579B2 (en)
CN (1) CN1132011C (en)
AT (1) ATE201772T1 (en)
AU (1) AU693808B2 (en)
CA (1) CA2172961A1 (en)
DE (1) DE69427364T2 (en)
DK (1) DK0721586T3 (en)
WO (1) WO1995009365A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107457A (en) * 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5969101A (en) * 1995-10-27 1999-10-19 Duke University ABL-interactor protein
WO1998024902A1 (en) * 1996-12-03 1998-06-11 Sugen, Inc. Adaptor protein frs2 and related products and methods
AU7821798A (en) * 1997-06-09 1998-12-30 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6768165B1 (en) * 1997-08-01 2004-07-27 Saifun Semiconductors Ltd. Two bit non-volatile electrically erasable and programmable semiconductor memory cell utilizing asymmetrical charge trapping
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US20030064061A1 (en) * 2001-07-09 2003-04-03 Whitehead Institute For Biomedical Research Bcr-Abl oligomerization domain polypeptides and uses therefor
US20030083304A1 (en) * 2001-10-09 2003-05-01 Smart Robert C. CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
WO2011034919A2 (en) * 2009-09-15 2011-03-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
EP3307328A1 (en) * 2015-06-10 2018-04-18 Universität des Saarlandes Means and methods for treatment of b-cell malignancies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1994011392A1 (en) * 1992-11-06 1994-05-26 Warner-Lambert Company Peptide inhibitors of tyrosine kinases and therapeutic uses thereof
CA2113494A1 (en) * 1994-01-14 1995-07-15 Lorri Puil Method for assaying for substances which affect bcr-abl mediated transformation

Also Published As

Publication number Publication date
AU693808B2 (en) 1998-07-09
JPH09505730A (en) 1997-06-10
US20030092079A1 (en) 2003-05-15
EP0721586A4 (en) 1996-09-25
US6066463A (en) 2000-05-23
DE69427364D1 (en) 2001-07-05
CN1132011C (en) 2003-12-24
WO1995009365A1 (en) 1995-04-06
EP0721586A1 (en) 1996-07-17
AU7846494A (en) 1995-04-18
CA2172961A1 (en) 1995-04-06
ATE201772T1 (en) 2001-06-15
US6528270B1 (en) 2003-03-04
DK0721586T3 (en) 2001-07-30
EP0721586B1 (en) 2001-05-30
JP3606579B2 (en) 2005-01-05
CN1137826A (en) 1996-12-11

Similar Documents

Publication Publication Date Title
MX9709442A (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions.
DE69427364T2 (en) METHOD AND COMPOSITIONS FOR TREATING BCR-ABL ASSOCIATED LEUKEMIA AND OTHER CELL-POLLIFERATIVE DISORDERS
DE60027551D1 (en) COMPOSITIONS AND METHOD FOR REGULATING THE SERUM CHOLESTEROL
DE69634912D1 (en) INTRA-CELLULAR DOMAIN OF HER-2 / NEU PROTEIN, FOR THE PREVENTION OR TREATMENT OF SOMETHING TUMORS
ATE333888T1 (en) USE OF A POLYPEPTIDE CONTAINING THE EXTRACELLULAR DOMAIN OF IL-20RA AND IL-20RB FOR THE TREATMENT OF INFLAMMATION
DE69805973D1 (en) TREATING HEART CRYSTAL DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM / CALMODULIN-DEPENDENT PROTEIN KINASE
ATE296116T1 (en) A COVALENT CONJUGATE OF CLOZAPINE AND A FATTY ACID AND THE USE THEREOF FOR THE TREATMENT OF SCHIZOPHRENIA
MX9702170A (en) Use of aromatase inhibitors in the preparation of a drug for treating a relative androgen deficiency in men.
ES8702431A1 (en) Blood coagulation inhibiting proteins, process for preparing them and their use.
DE69325393D1 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD USING ISOBUTYRAMIDE FOR THE TREATMENT OF BETAGLOBIN DISEASES
DE60025008D1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
ATE231970T1 (en) METHOD FOR MEASURING CHEMICAL AND PHYSICAL PARAMETERS FOR CHARACTERIZATION AND CLASSIFICATION OF AQUEOUS SUSPENSIONS
EP0915989A4 (en) Assays for protein kinases using fluorescent protein substrates
ES2216630T3 (en) METHODS OF TREATING DEPENDENT HYPERTENSION OF SALT.
TR199700999T1 (en) Ascomycins.
ATE302002T1 (en) USE OF PYRAZOLE DERIVATIVES TO TREAT INFERTILITY
NO20010389D0 (en) Modulation of multiple line kinase proteins
DE69433243D1 (en) Use of ApoE to bind TAU and MAP2c proteins and to treat Alzheimer's disease
DE69808475T2 (en) AMINO ACID DERIVATIVES FOR TREATING STROKE
DE60024997D1 (en) VGF POLYPEPTIDES AND METHOD FOR THE TREATMENT OF VGF DISEASES
DE69228814D1 (en) METHOD FOR PREVENTING AND TREATING ALOPECIA CAUSED BY CHEMOTHERAPY
DE60140074D1 (en) Non-apoptotic forms of cell death and method of modulation
FI973469A (en) Process for the preparation of factor IX from biological sources
DE69330465T2 (en) METHOD FOR TREATING CHRONIC PROSTATITIS WITH 17-BETA-N-TERTBUTYLCARBAMOYL-4-AZA-5 ALPHA-ANDROST-1-EN-3-ONE
ATE312179T1 (en) AGENT CONTAINING SERINE-THREONINE KINASE FOR TUMOR THERAPY AND TUMOR DIAGNOSIS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEW YORK UNIVERSITY, NEW YORK, N.Y., US

Owner name: SUGEN, INC., SAN FRANCISCO, CALIF., US

Owner name: DUKE UNIVERSITY, DURHAM, N.C., US

8339 Ceased/non-payment of the annual fee